Bausch & Lomb (BLCO) Q3 2025 Earnings
Reported Oct 29, 2025 at 7:02 AM ET · SEC Source
Q3 25 EPS
$0.18
BEAT +11.87%
Est. $0.16
Q3 25 Revenue
$1.28B
BEAT +0.25%
Est. $1.28B
vs S&P Since Q3 25
+4.7%
BEATING MARKET
BLCO +13.0% vs S&P +8.3%
Market Reaction
Did BLCO Beat Earnings? Q3 2025 Results
Bausch + Lomb delivered a solid third quarter, posting adjusted EPS of $0.18 against a consensus estimate of $0.16, a 12.50% beat, as broad-based revenue growth and improving operational efficiency carried the eye-health company ahead of expectations… Read more Bausch + Lomb delivered a solid third quarter, posting adjusted EPS of $0.18 against a consensus estimate of $0.16, a 12.50% beat, as broad-based revenue growth and improving operational efficiency carried the eye-health company ahead of expectations. Revenue rose 7.1% year-over-year to $1.28 billion, with all three segments contributing, led by Vision Care at $736.00 million and Pharmaceuticals at $330.00 million, the latter buoyed by strong uptake of MIEBO in the dry eye market. Operating income more than doubled to $95.00 million from $43.00 million a year ago, reflecting higher sales volumes and tighter expense management, though a swing in the tax provision pushed the GAAP result to a net loss of $28.00 million. Adjusted EBITDA climbed to $243.00 million from $212.00 million. Shares rose in pre-market trading on the profitability beat, and management reinforced confidence by narrowing full-year 2025 Adjusted EBITDA guidance to $870.00 million-$910.00 million while maintaining revenue guidance of $5.05 billion-$5.15 billion.
Key Takeaways
- • Over-the-counter dry eye portfolio and eye vitamins growth in Vision Care consumer business
- • Growth in SiHy Daily lenses and Biotrue ONEday in contact lens business
- • Strong growth in MIEBO driving Pharmaceuticals segment
- • International Pharmaceuticals growth
- • Premium IOL growth in enVista and LUX platforms in Surgical segment
- • Operating expense efficiencies
BLCO YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
BLCO Revenue by Segment
With YoY comparisons, source: SEC Filings
“We're delivering on the vision we laid out in 2023, with a base business engine that continues to hum and steady introduction of innovative products across categories.”
— Brent Saunders, Q3 2025 Earnings Press Release
BLCO Earnings Trends
BLCO vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BLCO EPS Trend
Earnings per share: estimate vs actual
BLCO Revenue Trend
Quarterly revenue: estimate vs actual
BLCO Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $0.05 | $0.05 | -6.72% | $1.24B | +2.33% |
| Q4 25 MISS FY | $0.36 | $0.32 | -10.29% | $1.41B | +1.44% |
| FY Full Year | — | $0.43 | — | $5.10B | — |
| Q3 25 BEAT | $0.16 | $0.18 | +11.87% | $1.28B | +0.25% |
| Q2 25 MISS | $0.08 | $0.07 | -16.86% | $1.28B | +1.78% |